PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 14, 2023New England Journal of Medicine333 citationsOpen Access

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia

RCRobert ChiesaCGChristos GeorgiadisFSFarhatullah Syed

Key Points

  • This study aims to evaluate the safety and efficacy of base-edited CAR7 T cells in patients with relapsed T-cell acute lymphoblastic leukemia.
  • Phase 1 clinical trial design
  • Patients receiving base-edited CAR7 T cells
  • Interim results assessed for safety and efficacy
  • Interim results indicate promising safety profile of base-edited T cells in relapsed leukemia patients.
  • Study suggests further investigation is warranted due to potential immunotherapy-related complications.

Abstract

The interim results of this phase 1 study support further investigation of base-edited T cells for patients with relapsed leukemia and indicate the anticipated risks of immunotherapy-related complications. (Funded by the Medical Research Council and others; ISRCTN number, ISRCTN15323014.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chiesa et al. (2023) studied this question.

synapsesocial.com/papers/69de8533353721b241b0c0f1https://doi.org/10.1056/nejmoa2300709
Ask AI
Helpful
Bookmark
Share
View Full Paper